Actively Recruiting

Age: 18Years +
All Genders
NCT06476119

OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

Led by The Netherlands Cancer Institute · Updated on 2025-04-23

490

Participants Needed

28

Research Sites

491 weeks

Total Duration

On this page

Sponsors

T

The Netherlands Cancer Institute

Lead Sponsor

M

Maarten van de Weijden Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

The aim of this study is to investigate whether subjects with breast cancer that have certain favorable features, after performing the surgery and radiation, the chemotherapy can be safely omitted in the treatment. In addition, the investigation looks at whether the omission of chemotherapy ensures a better quality of life. Participants decide, in consultation with their treating physician, whether they choose to be treated with adjuvant chemotherapy or not.

CONDITIONS

Official Title

OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Female or male patients
  • Age 18 years or older
  • Written informed consent given
  • Diagnosis of triple-negative breast cancer (TNBC) confirmed by biopsy and surgical specimen
  • Pathological stage I TNBC with tumor size 2 cm or less and no lymph node metastases
  • No signs of cancer spread on imaging tests including PET/CT or CT scans
  • High stromal tumor-infiltrating lymphocytes score (at least 50% or 75% depending on age) confirmed on tissue samples
  • Completed curative breast surgery including lymph node staging
  • No breast cancer recurrence after surgery
  • Eligible for radiotherapy if needed
Not Eligible

You will not qualify if you...

  • Previous or ongoing invasive or non-invasive breast cancer
  • Multifocal, multicentric, or bilateral breast cancer at screening
  • Received neoadjuvant systemic therapy
  • Presence of lymphovascular invasion in biopsy or surgical specimen
  • Other invasive cancers within 5 years except certain treated skin, cervical, or prostate cancers
  • Uncontrolled severe illness or medical condition
  • Any psychological, family, social, or geographic issues preventing study compliance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 28 locations

1

Zuyderland Medisch Centrum

Sittard-Geleen, Limburg, Netherlands, 6162 BG

Not Yet Recruiting

2

Medical spectrum Twente

Enschede, Overijssel, Netherlands, 7500 KA

Actively Recruiting

3

Noordwest Ziekenhuisgroep

Alkmaar, Netherlands

Not Yet Recruiting

4

Flevoziekenhuis

Almere Stad, Netherlands

Not Yet Recruiting

5

Meander Medisch Centrum

Amersfoort, Netherlands

Actively Recruiting

6

Antoni van Leeuwenhoek

Amsterdam, Netherlands, 1066 CX

Actively Recruiting

7

Onze Lieve Vrouwe Gasthuis (OLVG)

Amsterdam, Netherlands

Actively Recruiting

8

Rijnstate

Arnhem, Netherlands

Actively Recruiting

9

Amphia ziekenhuis

Breda, Netherlands

Actively Recruiting

10

Deventer Ziekenhuis

Deventer, Netherlands

Actively Recruiting

11

Ziekenhuis Gelderse Vallei

Ede, Netherlands

Actively Recruiting

12

Catharina Ziekenhuis

Eindhoven, Netherlands

Actively Recruiting

13

Jeroen Bosch ziekenhuis

Eindhoven, Netherlands

Actively Recruiting

14

St. Jansdal

Harderwijk, Netherlands

Actively Recruiting

15

Ziekenhuisgroep Twente

Hengelo, Netherlands

Actively Recruiting

16

Tergooi ziekenhuizen

Hilversum, Netherlands

Actively Recruiting

17

Spaarne Gasthuis

Hoofddorp, Netherlands

Actively Recruiting

18

Dijklander ziekenhuis

Hoorn, Netherlands

Not Yet Recruiting

19

MCL

Leeuwarden, Netherlands, 8934 AD

Not Yet Recruiting

20

LUMC

Leiden, Netherlands

Not Yet Recruiting

21

MUMC

Maastricht, Netherlands

Not Yet Recruiting

22

St. Antonius ziekenhuis

Nieuwegein, Netherlands

Actively Recruiting

23

Radboud UMC

Nijmegen, Netherlands, 6225GA

Not Yet Recruiting

24

Erasmus Medical Center Cancer Institute

Rotterdam, Netherlands, 3015CE

Not Yet Recruiting

25

Franciscus Gasthuis & Vlietland

Schiedam, Netherlands

Actively Recruiting

26

Haaglanden Medisch Centrum

The Hague, Netherlands

Actively Recruiting

27

VieCuri Medisch Centrum voor Noord-Limburg

Venlo, Netherlands

Not Yet Recruiting

28

Isala

Zwolle, Netherlands

Actively Recruiting

Loading map...

Research Team

M

Marleen Kok, MD

CONTACT

R

Rianne Rolfes, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes | DecenTrialz